Related Content
Search Google Scholar for:
|
|
Science 5 July 1985:
Vol. 229. no. 4708, pp. 81 - 83
DOI: 10.1126/science.3925553
|
|
Articles
Science, Vol 229, Issue 4708, 81-83
Copyright © 1985 by American Association for the Advancement of Science
Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments
M Brennan,
PF Davison,
and
H Paulus
Preparation of bispecific antibodies by the chemical reassociation of monovalent fragments derived from monoclonal mouse immunoglobulin G1 is inefficient because of side reactions during reoxidation of the multiple disulfide bonds linking the heavy chains. These side reactions can be avoided by using specific dithiol complexing agents such as arsenite and effecting disulfide formation with a thiol activating agent such as 5,5'-dithiobis(2-nitrobenzoic acid). In this way bispecific antibodies were obtained in high yield and free of monospecific contaminants from monoclonal mouse immunoglobulin G1 fragments. The bispecific antibodies were used as agents for the selective immobilization of enzymes.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Suppression of Normal and Malignant Kit Signaling by a Bispecific Antibody Linking Kit with CD300a.
- I. Bachelet, A. Munitz, B. Berent-Maoz, D. Mankuta, and F. Levi-Schaffer (2008)
J. Immunol.
180, 6064-6069
| Abstract »
| Full Text »
| PDF »
- Imaging Experimental Atherosclerotic Lesions in ApoE Knockout Mice: Enhanced Targeting with Z2D3-Anti-DTPA Bispecific Antibody and 99mTc-Labeled Negatively Charged Polymers.
- B.-A. Khaw, Y. Tekabe, and L. L. Johnson (2006)
J. Nucl. Med.
47, 868-876
| Abstract »
| Full Text »
| PDF »
- Single Variable Domain-IgG Fusion: A NOVEL RECOMBINANT APPROACH TO Fc DOMAIN-CONTAINING BISPECIFIC ANTIBODIES.
- J. Shen, M. D. Vil, X. Jimenez, M. Iacolina, H. Zhang, and Z. Zhu (2006)
J. Biol. Chem.
281, 10706-10714
| Abstract »
| Full Text »
| PDF »
- Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers.
- G. P. Adams, M.-S. Tai, J. E. McCartney, J. D. Marks, W. F. Stafford III, L.L. Houston, J. S. Huston, and L. M. Weiner (2006)
Clin. Cancer Res.
12, 1599-1605
| Abstract »
| Full Text »
| PDF »
- Application of Bispecific F(ab')2{micro} Fragments Prepared from IgMs against Carcinoembryonic Antigen and Alkaline Phosphatase.
- K. Morimoto and K. Inouye (2000)
Clin. Chem.
46, 1492-1493
| Full Text »
| PDF »
- Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 CD19 Tandem Diabody, and CD28 Costimulation.
- B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, J. Schuhmacher, A. Benner, G. Moldenhauer, and M. Little (2000)
Cancer Res.
60, 4336-4341
| Abstract »
| Full Text »
- Treatment of Human B Cell Lymphoma Xenografts with a CD3 CD19 Diabody and T Cells.
- B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, O. Christ, J. Schuhmacher, G. Strau{beta}, G. Moldenhauer, and M. Little (2000)
J. Immunol.
165, 888-895
| Abstract »
| Full Text »
| PDF »
- Tumor Therapy with Bispecific Antibody: The Targeting and Triggering Steps Can Be Separated Employing a CD2-Based Strategy.
- M. K. Wild, W. Strittmatter, S. Matzku, B. Schraven, and S. C. Meuer (1999)
J. Immunol.
163, 2064-2072
| Abstract »
| Full Text »
| PDF »
- In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model.
- J. De Jonge, C. Heirman, M. d. Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans (1998)
J. Immunol.
161, 1454-1461
| Abstract »
| Full Text »
| PDF »
- Intracellular Targeting with Low pH-triggered Bispecific Antibodies.
- V. Raso, M. Brown, and J. McGrath (1997)
J. Biol. Chem.
272, 27623-27628
| Abstract »
| Full Text »
| PDF »
- Antibody-Mediated Bacteriorhodopsin Orientation for Molecular Device Architectures.
- K. Koyama, N. Yamaguchi, and T. Miyasaka (1994)
Science
265, 762-765
| Abstract »
| PDF »
|
|
